Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Delta9-THC exposure-impaired hippocampal synaptic plasticity

J Neurochem. 2010 Feb;112(3):691-702. doi: 10.1111/j.1471-4159.2009.06489.x. Epub 2009 Nov 11.

Abstract

Chronic use of marijuana impairs synaptic plasticity and cognitive function. However, the molecular mechanisms by which marijuana alters long-term synaptic plasticity are largely unknown. Here, we show that repeated in vivo exposures to Delta9-THC for 7 consecutive days significantly impaired hippocampal long-term potentiation (LTP) of excitatory glutamatergic synaptic transmission. The Delta9-THC exposure-induced decrease in LTP was prevented by pharmacological inhibition or deletion of the cannabinoid 1 receptor (CB1R). To determine the molecular mechanisms underlying Delta9-THC-altered LTP, we targeted expression and function of the glutamate receptors (GluR) and phosphorylation status of cAMP-response element-binding protein (CREB). Chronic in vivo exposure to Delta9-THC produced CB1R-dependent decreases in expression of hippocampal GluR1, NR2A, and NR2B, the ratio of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)/NMDA receptor-gated currents, and phosphorylation of CREB. Our results suggest that reduced expression and function of the GluR subunits and phosphorylation of CREB may underlie the impaired long-term synaptic plasticity induced by repeated in vivo exposure to Delta9-THC.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • 2-Amino-5-phosphonovalerate / pharmacology
  • Animals
  • Bicuculline / pharmacology
  • Biophysics
  • Biotinylation
  • CREB-Binding Protein / metabolism*
  • Dronabinol / pharmacology*
  • Electric Stimulation / methods
  • Excitatory Amino Acid Antagonists / pharmacology
  • Excitatory Postsynaptic Potentials / drug effects
  • Excitatory Postsynaptic Potentials / genetics
  • GABA Antagonists / pharmacology
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / physiology*
  • Hippocampus / cytology*
  • Hippocampus / drug effects
  • In Vitro Techniques
  • Long-Term Potentiation / drug effects*
  • Long-Term Potentiation / genetics
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Patch-Clamp Techniques / methods
  • Phosphorylation / drug effects
  • Psychotropic Drugs / pharmacology
  • Receptor, Cannabinoid, CB1 / deficiency
  • Receptors, AMPA / genetics
  • Receptors, AMPA / metabolism
  • Receptors, Glutamate / genetics
  • Receptors, Glutamate / metabolism*
  • Receptors, N-Methyl-D-Aspartate / genetics
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • Synapses / drug effects*

Substances

  • Excitatory Amino Acid Antagonists
  • GABA Antagonists
  • NR2A NMDA receptor
  • NR2B NMDA receptor
  • Psychotropic Drugs
  • Receptor, Cannabinoid, CB1
  • Receptors, AMPA
  • Receptors, Glutamate
  • Receptors, N-Methyl-D-Aspartate
  • 2-Amino-5-phosphonovalerate
  • Dronabinol
  • CREB-Binding Protein
  • glutamate receptor ionotropic, AMPA 1
  • Bicuculline